Diabetes Drug Of India’s Dr. Reddy’s Hits Danish Trial Firm Problems
This article was originally published in PharmAsia News
Executive Summary
A Danish company conducting a Phase III trial on a diabetes drug for India's Dr. Reddy's Laboratories has encountered financial problems, possibly delaying the drug's introduction. Rheoscience has the Indian drug maker's balaglitizone in trials as a treatment for Type 2 diabetes and the drug was considered ahead of Indian competitors with launching possible as early as 2011. If Rheoscience cannot finish the trials, its parent, Nordic Bioscience is considered likely to finish them. (Click here for more